Longeveron jumps as FDA greenlights IND for stem cell trial
Longeveron (NASDAQ:LGVN) said on Tuesday that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potential…
Share